The present review details a chronological description of the events that took place during
the development of mesoporous materials, their different synthetic routes and their use as …

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer
drugs are organic molecules, while metallodrugs are very scarce. The advent of the first …

This manuscript reviews the recent progress on mesoporous silica nanoparticles as drug
delivery systems. Their intrinsic structural, textural and chemical features permit to design …

Tumor hypoxia is one of the major challenges for the treatment of tumors, as it may
negatively affect the efficacy of various anticancer modalities. In this study, a tumor-targeted …

Ruthenium (II)[Ru (II)] polypyridyl complexes have been the focus of intense investigations
since work began exploring their supramolecular interactions with DNA. In recent years …

Porous silica‐based materials have burgeoning applications ranging from fillers and
additives, to adsorbents, catalysts, and recently therapeutic agents and vaccines in …

Targeted drug delivery refers to an established therapeutic strategy that develops platforms
and nanoscale devices for selective delivery of small drug molecules and therapeutic genes …

Ruthenium (II) and iridium (III) coordination compounds display excellent structural,
photophysical, and biological properties which make them highly promising as anticancer …

The success of several FDA-approved platinum anticancer drugs has stimulated increasing
interest in the development of new metallodrugs.[1] Ruthenium (Ru) complexes are potential …

Introduction: Mesoporous silica nanoparticles (MSNPs) are one of the most promising
inorganic drug delivery systems (DDSs). The design and development of tumour-targeted …